Ekso Bionics Hlds

Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ekso Bionics reports record sales and margin growth in Q2 2024

Ekso Bionics delivered a strong performance in Q2 2024 with record sales, improved gross margins, and effective cost management.
The company's focus on expanding relationships, receiving Medicare reimbursement, and collaborations in neurorehabilitation centers position it well for growth.
While facing challenges in competitive industrial segments and margin sustainability, Ekso Bionics has opportunities to leverage international demand and market expansion.

Ekso Bionics reports solid Q3 performance, eyes global expansion

Ekso Bionics demonstrated solid performance in Q3 2024 with improved operational efficiency and strong international sales, despite challenges in the U.S. market.
The company's focus on market education, product reimbursement, and cost management positions it well for future growth and market expansion.
While facing challenges in achieving profitability and managing U.S. sales fluctuations, Ekso Bionics has opportunities to capitalize on its strengths and drive further growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q3 2020 Results - Earnings Call Transcript

RICHMOND, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended September 30, 2020.

Ekso Bionics Reports Third Quarter 2020 Results

A c utting-edge endurance-boosting assistive device , E VO is designed to reduce the risk of repetitive or fatigue-related injuries for construction workers and other industrial employees

Ekso Bionics Announces EGM Builders as First Customer to Adopt EVO Technology

RICHMOND, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2020 after the close of trading on Thursday, October 29, 2020. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics® to Report Third Quarter 2020 Financial Results on October 29, 2020

RICHMOND, Calif., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack Glenn, Chief Financial Officer of Ekso Bionics, will present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference at 11:30 am ET / 8:30 am PT on Wednesday, September 16, 2020.

Ekso Bionics to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 16, 2020

﻿RICHMOND, Calif., Aug.  20, 2020  (GLOBE NEWSWIRE) --  Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”) , an industry leader in exoskeleton technology for medical and industrial use, today unveiled EVOTM, an endurance-boosting assistive upper body exoskeleton that alleviates the burden of repetitive work. Building on the Company’s trailblazing EksoVest technology, EVO’s innovative design is the next step in the evolution of industrial exoskeletons.

Ekso Bionics® Unveils its Latest Assistive Exoskeleton Innovation for Industrial Use

Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q2 2020 Results - Earnings Call Transcript

Ekso Bionics (EKSO) Q2 earnings are expected to have been boosted by its recent efforts to grow virtual connectivity with customers and to reduce costs.

Will Delayed Orders Hurt Ekso Bionics (EKSO) Q2 Earnings?

RICHMOND, Calif., July  23, 2020  (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2020 after the close of trading on Thursday, July 30, 2020. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics® to Report Second Quarter 2020 Financial Results on July 30, 2020

WASHINGTON and RICHMOND, Calif., July  09, 2020  (GLOBE NEWSWIRE) -- The  Army Distaff Foundation (ADF) , a non-profit charity in Washington, D.C., which operates Knollwood Military Life Plan  Community, is the first life plan community to adopt the use of Ekso Bionics’ (Nasdaq: EKSO) robotic exoskeleton for rehabilitation with aging adult populations.

Army Distaff Foundation-Knollwood is First Life Plan Community to Adopt Ekso Bionics’ Exoskeleton Device for Rehabilitation Following Successful Trial

Ekso Bionics Holdings (NASDAQ: EKSO) shares were trading higher Friday on continued strength after the company received FDA clearance to market its EksoNR robotic exoskeleton.

Why Ekso Bionics Stock Is Trading Higher Today

Ekso Bionics (EKSO) news for Thursday concerning approval from the FDA for one of its devices has EKSO stock soaring higher.

Ekso Bionics News: Why EKSO Stock Is Skyrocketing 139% Today

Shares of Ekso Bionics Holdings Inc. EKSO, 130.85% soared Thursday, after the company said it has received 501 clearance from the U.S. Food and Drug Administration to market its EksoNR robotic exoskeleton for use in patients with acquired brain injury, or ABI.

Ekso Bionics shares soar after company gets FDA clearance to use robotic exoskeleton in acquired brain injury

RICHMOND, Calif., June  25, 2020  (GLOBE NEWSWIRE) --  Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”) , an industry leader in exoskeleton technology for medical and industrial use, today announced it has received 501(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNRTM robotic exoskeleton for use with patients with acquired brain injury (ABI). EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use with ABI, significantly expanding the device’s indication to a broader group of patients.

Ekso Bionics® Receives FDA Clearance to Market its EksoNR™ Robotic Exoskeleton for Use with Acquired Brain Injury Patients

Ekso Bionics (EKSO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Ekso Bionics (EKSO) a New Buy Stock

RICHMOND, Calif., June  10, 2020  (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced registered direct offering of 1,747,704 shares of its common stock at a purchase price of $4.5145 per share and the concurrent private placement of warrants to purchase up to 873,852 shares of its common stock issued to the accredited investors in the registered direct offering priced at-the-market under Nasdaq Rules, for aggregate gross proceeds of approximately $7.89 million. The warrants are immediately exercisable, have an exercise price of $5.18 per share and a term of five and one-half years from the issuance date.

Ekso Bionics Announces Closing of $7.89 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

RICHMOND, Calif., June  08, 2020  (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,747,704 of its shares of common stock, at a purchase price of $4.5145 per share, in a registered direct offering priced at-the-market under Nasdaq Rules. The Company has also agreed to issue to the investors in a concurrent private placement warrants to purchase up to an aggregate of 873,852 shares of common stock. The closing of the offering is expected to occur on or about June 10, 2020, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.  The warrants have an exercise price equal to $5.18 per share, are exercisable immediately and will expire five and one-half years from the issuance date. The gross proceeds from the offering are expected to be approximately $7.89 million. The Company intends to use the net proceeds from the offering for working capital purposes and other general corporate purposes.  The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) are being offered and sold by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-218517), including an accompanying base prospectus, previously filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”) on June 16, 2017. The offering of the shares of common stock will be made only by means of a prospectus supplement to the base prospectus that forms a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering of the shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at placements@hcwco.com.   The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act"), and Regulation D promulgated thereunder. The offer and sale of the warrants and the shares of common stock underlying the warrants have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and the underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  About Ekso Bionics®

Ekso Bionics Announces $7.89 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies

Ekso Bionics® Named “Best Healthcare Robotics Company” in 2020 MedTech Breakthrough Awards Program

RICHMOND, Calif., May  20, 2020  (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported that the Company, Zhejiang Youchuang Venture Capital Investment Co., Ltd and another partner (collectively, the “JV Partners”) received notice from the Committee on Foreign Investment in the United States (“CFIUS”) in connection with its review of the Company’s and the JV Partners’ investment in Exoskeleton Intelligent Robotics Co. Limited (the “JV”).  The notice states that CFIUS’s prior national security concerns regarding the JV could not be mitigated and, in connection with its determination, CFIUS presented the Company and the JV Partners with a National Security Agreement (“NSA”), which will, among other things, require the termination of the Company’s role with the JV. The Company intends to work cooperatively with the JV Partners and CFIUS to finalize the terms of the NSA.

Ekso Bionics Announces CFIUS Determination Regarding China Joint Venture

Entasis Therapeutics Holdings Inc

Wall Street sell-side analysts are positive about Ekso Bionics Holdings Inc (NASDAQ:EKSO) and Entasis Therapeutics Holdings Inc (NASDAQ:ETTX), even though their holdings have lost more than 59% over the past 52 weeks.

Analysts Suggest Buying These 2 Falling Knives

Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q1 2020 Results - Earnings Call Transcript

- Company Regains Nasdaq Listing Compliance -

Ekso Bionics Provides COVID-19 Business Update and Reports Preliminary First Quarter 2020 Financial Results

RICHMOND, Calif., March  24, 2020  (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of March 24, 2020 at 1:05 p.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Market on March 25, 2020 on a split-adjusted basis under the existing trading symbol “EKSO”. The Company’s common stock will trade under a new CUSIP number 282644301 upon the effectiveness of the reverse stock split.

Ekso Bionics® Announces Reverse Stock Split

Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q4 2019 Results - Earnings Call Transcript

RICHMOND, Calif., Feb.  25, 2020  (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced a collaboration with Kindred Healthcare, LLC ("Kindred") to pilot EksoNR— the most clinically used robotic exoskeleton, in their long-term acute care hospitals.

News for Ekso Bionics Hlds Stock (EKSO)